62845-95-8

Basic information

• Product Name: Methanesulfonamide, 1-chloro-N-phenyl-
• CAS NO: 62845-95-8
• Molecular Formula: C7H8ClNO2S
• Molecular Weight: 205.665
• Mol File: 62845-95-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Methanesulfonamide, 1-chloro-N-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Methanesulfonamide, 1-chloro-N-phenyl-(62845-95-8)
• EPA Substance Registry System: Methanesulfonamide, 1-chloro-N-phenyl-(62845-95-8)

Safety Data

• Hazardous Substances Data: 62845-95-8(Hazardous Substances Data)

Upstream product

• 3518-65-8 monochloromethanesulfonyl chloride 
• 62-53-3 aniline 

Downstream Products

• 143032-56-8 C-Chloro-N-(2-fluoro-5-nitro-benzyl)-N-phenyl-methanesulfonamide 
• 143032-54-6 C-Chloro-N-(4-methoxy-3-nitro-benzyl)-N-phenyl-methanesulfonamide 
• 99310-51-7 4-chloro-N-chloromethanesulfonyl-N-trichloromethanesulfenyl-aniline 
• 143032-28-4 7-Methoxy-8-nitro-3-phenyl-3,4-dihydro-1H-benzo[d][1,2]thiazine 2,2-dioxide 
• 143032-29-5 7-Methoxy-6-nitro-3-phenyl-3,4-dihydro-1H-benzo[d][1,2]thiazine 2,2-dioxide 
• 143032-30-8 7-Chloro-8-nitro-3-phenyl-3,4-dihydro-1H-benzo[d][1,2]thiazine 2,2-dioxide 
• 143032-31-9 7-Chloro-6-nitro-3-phenyl-3,4-dihydro-1H-benzo[d][1,2]thiazine 2,2-dioxide 
• 143032-26-2 7-Methyl-8-nitro-3-phenyl-3,4-dihydro-1H-benzo[d][1,2]thiazine 2,2-dioxide 
• 143032-27-3 7-Methyl-6-nitro-3-phenyl-3,4-dihydro-1H-benzo[d][1,2]thiazine 2,2-dioxide 
• 143032-25-1 6-Nitro-3-phenyl-3,4-dihydro-1H-benzo[d][1,2]thiazine 2,2-dioxide 
• 134334-58-0 5-Fluoro-8-nitro-3-phenyl-3,4-dihydro-1H-benzo[d][1,2]thiazine 2,2-dioxide 
• 134334-56-8 8-Nitro-3-phenyl-3,4-dihydro-1H-benzo[d][1,2]thiazine 2,2-dioxide 
• 86434-23-3 C-Chloro-N-(3-nitro-benzyl)-N-phenyl-methanesulfonamide 
• 143032-55-7 C-Chloro-N-(4-chloro-3-nitro-benzyl)-N-phenyl-methanesulfonamide 

Relevant articles and documents

Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout

As a part of our ongoing research to develop novel URAT1 inhibitors, 19 compounds (1a-1s) based on carboxylic acid bioisosteres were synthesized and tested for in vitro URAT1 inhibitor activity (IC50). The structure-activity relationship (SAR) exploration led to the discovery of a highly potent novel URAT1 inhibitor 1g, which was 225-fold more potent than the parent lesinurad in vitro (IC50 = 0.032 μM for 1g against human URAT1 vs 7.20 μM for lesinurad). Besides, 3D-QSAR pharmacophore models were established based on the activity of the compounds (1a-1s) by Accelrys Discovery Studio 2.5/HypoGen. The best hypothesis, Hypo 1, was validated by three methods (cost analysis, Fisher's randomization and leave-one-out). Although compound 1g is among the most potent URAT1 inhibitors currently under development in clinical trials, the Hypo1 appears to be favorable for future lead optimization.

Synthesis of benzosultams via intramolecular vicarious nucleophilic substitution of hydrogen

Intramolecular Vicarious Nucleophilic Substitution of Hydrogen (VNS) in N-(3-nitrophenyl)- and N-(3-nitrobenzyl)chloromethylsulfonamides leads to five-, six- and seven-membered benzosultam derivatives.